unbekannt und doch interessant - 500 Beiträge pro Seite
eröffnet am 14.01.11 16:08:05 von
neuester Beitrag 19.03.11 19:05:49 von
neuester Beitrag 19.03.11 19:05:49 von
Beiträge: 2
ID: 1.162.789
ID: 1.162.789
Aufrufe heute: 0
Gesamt: 726
Gesamt: 726
Aktive User: 0
ISIN: US1920051067 · WKN: A0Q2S4 · Symbol: CDXS
2,8000
USD
+1,45 %
+0,0400 USD
Letzter Kurs 22:30:00 Nasdaq
Neuigkeiten
22:05 Uhr · globenewswire |
11.04.24 · globenewswire |
28.02.24 · globenewswire |
26.02.24 · globenewswire |
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
3.000,00 | +74.900,00 | |
0,9300 | +54,46 | |
0,5010 | +40,65 | |
4,4700 | +38,39 | |
6,7900 | +36,35 |
Wertpapier | Kurs | Perf. % |
---|---|---|
5,0550 | -22,71 | |
2,4400 | -22,78 | |
6,0500 | -22,93 | |
0,9000 | -23,08 | |
1,2250 | -38,44 |
Erst seit einigen Monaten eigenständig an der Börse, wurde kürzlich ganz von Maxygen abgespalten.
Eine Meldung vom 12. Jan 11 hier mal zum Appetit holen
The agreement grants DSM rights to use Codexis' custom biocatalysts and services, and secures supply of Codexis enzymes for commercialization of sustainable enzyme-based pharmaceutical manufacturing routes developed by DSM's InnoSyn™ route scouting services.
Codexis technology enables development of new efficient manufacturing processes for active pharmaceutical ingredients and intermediates which reduce cost and environmental waste. Codexis technology is used at major pharmaceutical and chemical companies worldwide including Merck, Pfizer and Teva.
The DSM InnoSyn™ route scouting team provides value creating solutions to its customer by integrating cutting edge enzyme technology with the full range of advances in synthetic methods such as homogeneous catalysis, modern organic synthesis and continuous chemistry, using for example micro reactors. The new routes result in increased efficiency of the manufacturing processes while reducing cost and environmental impact.
"Codexis has a proven track record over nearly 10 years in bringing innovation and manufacturing efficiency to our partners," said Joseph Sarret, M.D., President, Codexis Pharmaceutical Services & Enzyme Products. "We are pleased to collaborate with DSM in the field of biocatalysis to enable cost-effective manufacturing process at commercial scale."
Oliver May, Ph.D., Corporate Scientist and Business Manager for DSM's InnoSyn™ route scouting services commented: "One important success factor for implementing enzymatic routes is access to a diverse range of biocatalysts. DSM is continuously expanding its unique enzyme collection of more than 3000 enzymes by in-house developments as well as innovative partnering models. We are very pleased to collaborate with Codexis whose expertise in enzyme development perfectly matches with DSM's capabilities to identify, develop and implement efficient enzymatic routes."
InnoSyn™ is a trademark of DSM
Codexis
Codexis (Nasdaq: CDXS) is a clean technology company that develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with many leading global pharmaceutical companies and in development for advanced biofuels with Shell. Other potential markets include carbon capture, water treatment and chemicals. More information: www.codexis.com
Eine Meldung vom 12. Jan 11 hier mal zum Appetit holen
The agreement grants DSM rights to use Codexis' custom biocatalysts and services, and secures supply of Codexis enzymes for commercialization of sustainable enzyme-based pharmaceutical manufacturing routes developed by DSM's InnoSyn™ route scouting services.
Codexis technology enables development of new efficient manufacturing processes for active pharmaceutical ingredients and intermediates which reduce cost and environmental waste. Codexis technology is used at major pharmaceutical and chemical companies worldwide including Merck, Pfizer and Teva.
The DSM InnoSyn™ route scouting team provides value creating solutions to its customer by integrating cutting edge enzyme technology with the full range of advances in synthetic methods such as homogeneous catalysis, modern organic synthesis and continuous chemistry, using for example micro reactors. The new routes result in increased efficiency of the manufacturing processes while reducing cost and environmental impact.
"Codexis has a proven track record over nearly 10 years in bringing innovation and manufacturing efficiency to our partners," said Joseph Sarret, M.D., President, Codexis Pharmaceutical Services & Enzyme Products. "We are pleased to collaborate with DSM in the field of biocatalysis to enable cost-effective manufacturing process at commercial scale."
Oliver May, Ph.D., Corporate Scientist and Business Manager for DSM's InnoSyn™ route scouting services commented: "One important success factor for implementing enzymatic routes is access to a diverse range of biocatalysts. DSM is continuously expanding its unique enzyme collection of more than 3000 enzymes by in-house developments as well as innovative partnering models. We are very pleased to collaborate with Codexis whose expertise in enzyme development perfectly matches with DSM's capabilities to identify, develop and implement efficient enzymatic routes."
InnoSyn™ is a trademark of DSM
Codexis
Codexis (Nasdaq: CDXS) is a clean technology company that develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with many leading global pharmaceutical companies and in development for advanced biofuels with Shell. Other potential markets include carbon capture, water treatment and chemicals. More information: www.codexis.com
der Kurssturz in Frankfurt war ohne Umsatz. In USA geht der Kurs nämlich nach oben und ein Zusammenhang mit Kursen in USA ist absolut nicht gegeben
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
+0,40 | |
+1,27 | |
-2,26 | |
+0,40 | |
+1,35 | |
-0,39 | |
+0,76 | |
-1,80 | |
-4,53 | |
-0,46 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
174 | ||
121 | ||
77 | ||
57 | ||
56 | ||
54 | ||
54 | ||
52 | ||
44 | ||
39 |
22:05 Uhr · globenewswire · Codexis |
11.04.24 · globenewswire · Codexis |
28.02.24 · globenewswire · Codexis |
26.02.24 · globenewswire · Codexis |
26.02.24 · globenewswire · Codexis |
Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board 20.02.24 · globenewswire · Codexis |
14.02.24 · globenewswire · Codexis |
13.02.24 · globenewswire · Codexis |
01.02.24 · globenewswire · Codexis |
27.12.23 · globenewswire · Codexis |
Zeit | Titel |
---|---|
06.03.24 |